Key Points
-
Germline alterations leading to aberrant cAMP-dependent protein kinase A (PKA) pathway activation can cause primary bilateral adrenal hyperplasia and Cushing syndrome
-
Cortisol-secreting adenomas can be caused by somatic mutations in genes encoding components of the cAMP–PKA pathway
-
Primary bilateral macronodular adrenal hyperplasia is frequently a genetic disorder caused by ARMC5 inactivating mutations
-
Intra-adrenal production of adrenocorticotropic hormone by steroidogenic cells contributes to dysregulated cortisol production in some types of adrenal hyperplasia, yielding potential new therapeutic targets for Cushing syndrome
Abstract
Primary adrenal Cushing syndrome is the result of cortisol hypersecretion mainly by adenomas and, rarely, by bilateral micronodular or macronodular adrenocortical hyperplasia. cAMP-dependent protein kinase A (PKA) signalling is the major activator of cortisol secretion in the adrenal cortex. Many adenomas and hyperplasias associated with primary hypercortisolism carry somatic or germline mutations in genes that encode constituents of the cAMP–PKA pathway. In this Review, we discuss Cushing syndrome and its linkage to dysregulated cAMP–PKA signalling, with a focus on genetic findings in the past few years. In addition, we discuss the presence of germline inactivating mutations in ARMC5 in patients with primary bilateral macronodular adrenocortical hyperplasia. This finding has implications for genetic counselling of affected patients; hitherto, most patients with this form of adrenal hyperplasia and Cushing syndrome were thought to have a sporadic and not a familial disorder.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Weinstein, L. S. et al. Activating mutations of the stimulatory G protein in the McCune–Albright syndrome. N. Engl. J. Med. 325, 1688–1695 (1991).
Groussin, L. et al. Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD. Am. J. Hum. Genet. 71, 1433–1442 (2002).
Horvath, A. et al. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat. Genet. 38, 794–800 (2006).
Horvath, A., Mericq, V. & Stratakis, C. A. Mutation in PDE8B, a cyclic AMP-specific phosphodiesterase in adrenal hyperplasia. N. Engl. J. Med. 358, 750–752 (2008).
Beuschlein, F. et al. Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome. N. Engl. J. Med. 370, 1019–1028 (2014).
Assie, G. et al. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. N. Engl. J. Med. 369, 2105–2114 (2013).
Louiset, E. et al. Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. N. Engl. J. Med. 369, 2115–2125 (2013).
Lacroix, A., Feelders, R. A., Stratakis, C. A. & Nieman, L. K. Cushing's syndrome. Lancet 386, 913–927 (2015).
Dekkers, O. M. et al. Multisystem morbidity and mortality in Cushing's syndrome: a cohort study. J. Clin. Endocrinol. Metab. 98, 2277–2284 (2013).
Graversen, D., Vestergaard, P., Stochholm, K., Gravholt, C. H. & Jorgensen, J. O. Mortality in Cushing's syndrome: a systematic review and meta-analysis. Eur. J. Intern. Med. 23, 278–282 (2012).
Michalkiewicz, E. et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J. Clin. Oncol. 22, 838–845 (2004).
Ng, L. & Libertino, J. M. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J. Urol. 169, 5–11 (2003).
Nieman, L. K. et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 93, 1526–1540 (2008).
Stratakis, C. A. Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin-independent Cushing syndrome). Endocr. Dev. 13, 117–132 (2008).
Lacroix, A. ACTH-independent macronodular adrenal hyperplasia. Best Pract. Res. Clin. Endocrinol. Metab. 23, 245–259 (2009).
Bourdeau, I. et al. Primary pigmented nodular adrenocortical disease: paradoxical responses of cortisol secretion to dexamethasone occur in vitro and are associated with increased expression of the glucocorticoid receptor. J. Clin. Endocrinol. Metab. 88, 3931–3937 (2003).
Nehs, M. A. & Ruan, D. T. Minimally invasive adrenal surgery: an update. Curr. Opin. Endocrinol. Diabetes Obes. 18, 193–197 (2011).
Taylor, S. S., Ilouz, R., Zhang, P. & Kornev, A. P. Assembly of allosteric macromolecular switches: lessons from PKA. Nat. Rev. Mol. Cell Biol. 13, 646–658 (2012).
Bourdeau, I. & Stratakis, C. A. Cyclic AMP-dependent signaling aberrations in macronodular adrenal disease. Ann. NY Acad. Sci. 968, 240–255 (2002).
Carney, J. A., Young, W. F. & Stratakis, C. A. Primary bimorphic adrenocortical disease: cause of hypercortisolism in McCune–Albright syndrome. Am. J. Surg. Pathol. 35, 1311–1326 (2011).
Brown, R. J., Kelly, M. H. & Collins, M. T. Cushing syndrome in the McCune–Albright syndrome. J. Clin. Endocrinol. Metab. 95, 1508–1515 (2010).
Fragoso, M. C. et al. Cushing's syndrome secondary to adrenocorticotropin-independent macronodular adrenocortical hyperplasia due to activating mutations of GNAS1 gene. J. Clin. Endocrinol. Metab. 88, 2147–2151 (2003).
Stratakis, C. A., Kirschner, L. S. & Carney, J. A. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J. Clin. Endocrinol. Metab. 86, 4041–4046 (2001).
Kirschner, L. S. et al. Mutations of the gene encoding the protein kinase A type I-α regulatory subunit in patients with the Carney complex. Nat. Genet. 26, 89–92 (2000).
Bertherat, J. et al. Mutations in regulatory subunit type 1A of cyclic adenosine 5′-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J. Clin. Endocrinol. Metab. 94, 2085–2091 (2009).
Horvath, A. et al. Mutations and polymorphisms in the gene encoding regulatory subunit type 1-α of protein kinase A (PRKAR1A): an update. Hum. Mutat. 31, 369–379 (2010).
Groussin, L. et al. A PRKAR1A mutation associated with primary pigmented nodular adrenocortical disease in 12 kindreds. J. Clin. Endocrinol. Metab. 91, 1943–1949 (2006).
Bertherat, J. et al. Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Res. 63, 5308–5319 (2003).
Gaujoux, S. et al. Wnt/β-catenin and 3′,5′-cyclic adenosine 5′-monophosphate/protein kinase A signaling pathways alterations and somatic β-catenin gene mutations in the progression of adrenocortical tumors. J. Clin. Endocrinol. Metab. 93, 4135–4140 (2008).
Stratakis, C. A. et al. Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease. Ann. Intern. Med. 131, 585–591 (1999).
Louiset, E. et al. The paradoxical increase in cortisol secretion induced by dexamethasone in primary pigmented nodular adrenocortical disease involves a glucocorticoid receptor-mediated effect of dexamethasone on protein kinase A catalytic subunits. J. Clin. Endocrinol. Metab. 94, 2406–2413 (2009).
Libe, R. et al. Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors. Clin. Cancer Res. 14, 4016–4024 (2008).
Rothenbuhler, A. et al. Identification of novel genetic variants in phosphodiesterase 8B (PDE8B), a cAMP-specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumours. Clin. Endocrinol. 77, 195–199 (2012).
Horvath, A. et al. A cAMP-specific phosphodiesterase (PDE8B) that is mutated in adrenal hyperplasia is expressed widely in human and mouse tissues: a novel PDE8B isoform in human adrenal cortex. Eur. J. Hum. Genet. 16, 1245–1253 (2008).
Cao, Y. et al. Activating hotspot L205R mutation in PRKACA and adrenal Cushing's syndrome. Science 344, 913–917 (2014).
Goh, G. et al. Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. Nat. Genet. 46, 613–617 (2014).
Sato, Y. et al. Recurrent somatic mutations underlie corticotropin-independent Cushing's syndrome. Science 344, 917–920 (2014).
Di Dalmazi, G. et al. Novel somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal Cushing's syndrome: a European multicentric study. J. Clin. Endocrinol. Metab. 99, E2093–E2100 (2014).
Wilmot Roussel, H. et al. Identification of gene expression profiles associated with cortisol secretion in adrenocortical adenomas. J. Clin. Endocrinol. Metab. 98, E1109–E1121 (2013).
Almeida, M. Q. & Stratakis, C. A. How does cAMP/protein kinase A signaling lead to tumors in the adrenal cortex and other tissues? Mol. Cell. Endocrinol. 336, 162–168 (2011).
Bouizar, Z. et al. 8Cl-cAMP modifies the balance between PKAR1 and PKAR2 and modulates the cell cycle, growth and apoptosis in human adrenocortical H295R cells. J. Mol. Endocrinol. 44, 331–347 (2010).
Basso, F. et al. Comparison of the effects of PRKAR1A and PRKAR2B depletion on signaling pathways, cell growth, and cell cycle control of adrenocortical cells. Hormone Metab. Res. 46, 883–888 (2014).
Robinson-White, A. et al. PRKAR1A mutations and protein kinase A interactions with other signaling pathways in the adrenal cortex. J. Clin. Endocrinol. Metab. 91, 2380–2388 (2006).
Lania, A. G. et al. Proliferation of transformed somatotroph cells related to low or absent expression of protein kinase a regulatory subunit 1A protein. Cancer Res. 64, 9193–9198 (2004).
Tsai, L. C., Shimizu-Albergine, M. & Beavo, J. A. The high-affinity cAMP-specific phosphodiesterase 8B controls steroidogenesis in the mouse adrenal gland. Mol. Pharmacol. 79, 639–648 (2011).
Calebiro, D. et al. PKA catalytic subunit mutations in adrenocortical Cushing's adenoma impair association with the regulatory subunit. Nat. Commun. 5, 5680 (2014).
Lodish, M. B. et al. Germline PRKACA amplification causes variable phenotypes that may depend on the extent of the genomic defect: molecular mechanisms and clinical presentations. Eur. J. Endocrinol. 172, 803–811 (2015).
Almeida, M. Q. et al. Activation of cyclic AMP signaling leads to different pathway alterations in lesions of the adrenal cortex caused by germline PRKAR1A defects versus those due to somatic GNAS mutations. J. Clin. Endocrinol. Metab. 97, E687–E693 (2012).
Gaujoux, S. et al. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers. Clin. Cancer Res. 16, 5133–5141 (2010).
Gatta-Cherifi, B. et al. Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines database. Eur. J. Endocrinol. 166, 269–279 (2012).
Shuch, B. et al. Adrenal nodular hyperplasia in hereditary leiomyomatosis and renal cell cancer. J. Urol. 189, 430–435 (2013).
Matyakhina, L. et al. Hereditary leiomyomatosis associated with bilateral, massive, macronodular adrenocortical disease and atypical cushing syndrome: a clinical and molecular genetic investigation. J. Clin. Endocrinol. Metab. 90, 3773–3779 (2005).
Alencar, G. A. et al. ARMC5 mutations are a frequent cause of primary macronodular adrenal hyperplasia. J. Clin. Endocrinol. Metab. 99, E1501–E1509 (2014).
Gagliardi, L. et al. ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia. J. Clin. Endocrinol. Metab. 99, E1784–E1792 (2014).
Faucz, F. R. et al. Macronodular adrenal hyperplasia due to mutations in an armadillo repeat containing 5 (ARMC5) gene: a clinical and genetic investigation. J. Clin. Endocrinol. Metab. 99, E1113–E1119 (2014).
Espiard, S. et al. ARMC5 mutations in a large cohort of primary macronodular adrenal hyperplasia: clinical and functional consequences. J. Clin. Endocrinol. Metab. 100, E926–E935 (2015).
Zilbermint, M. et al. Primary aldosteronism and ARMC5 variants. J. Clin. Endocrinol. Metab. 100, E900–E909 (2015).
Lacroix, A. et al. Aberrant G-protein coupled receptor expression in relation to adrenocortical overfunction. Clin. Endocrinol. 73, 1–15 (2010).
Libe, R. et al. Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing's syndrome. Eur. J. Endocrinol. 163, 129–138 (2010).
Hsiao, H. P. et al. Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors. J. Clin. Endocrinol. Metab. 94, 2930–2937 (2009).
Lacroix, A. Heredity and cortisol regulation in bilateral macronodular adrenal hyperplasia. N. Engl. J. Med. 369, 2147–2149 (2013).
Skogseid, B. et al. Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab. 75, 76–81 (1992).
Swords, F. M. et al. Impaired desensitization of a mutant adrenocorticotropin receptor associated with apparent constitutive activity. Mol. Endocrinol. 16, 2746–2753 (2002).
Tissier, F. et al. Mutations of β-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 65, 7622–7627 (2005).
Acknowledgements
This work was supported by the Intramural Research Program (IRP) of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH, Bethesda, Maryland 20892, USA.
Author information
Authors and Affiliations
Contributions
M.L. researched data and wrote the article. Both authors made substantial contribution to discussion of the content and reviewed and/or edited the manuscript before submission
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Lodish, M., Stratakis, C. A genetic and molecular update on adrenocortical causes of Cushing syndrome. Nat Rev Endocrinol 12, 255–262 (2016). https://doi.org/10.1038/nrendo.2016.24
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2016.24
This article is cited by
-
The effect of unilateral adrenalectomy on patients with primary bilateral macronodular adrenal hyperplasia
Hormones (2023)
-
The mystery of transient pregnancy-induced cushing’s syndrome: a case report and literature review highlighting GNAS somatic mutations and LHCGR overexpression
Endocrine (2023)
-
A novel nonsense mutation in ARMC5 causes primary bilateral macronodular adrenocortical hyperplasia
BMC Medical Genomics (2021)
-
Feedback inhibition of cAMP effector signaling by a chaperone-assisted ubiquitin system
Nature Communications (2019)